2. Academic Validation
  3. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor

NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor

  • Bioorg Med Chem Lett. 2011 May 15;21(10):2969-74. doi: 10.1016/j.bmcl.2011.03.054.
Italo Beria 1,  Roberto T Bossi,  Maria Gabriella Brasca,  Michele Caruso,  Walter Ceccarelli,  Gabriele Fachin,  Marina Fasolini,  Barbara Forte,  Francesco Fiorentini,  Enrico Pesenti,  Daniele Pezzetta,  Helena Posteri,  Alessandra Scolaro,  Stefania Re Depaolini,  Barbara Valsasina
Affiliations

Affiliation

  • 1 Nerviano Medical Sciences srl, Business Unit Oncology, Viale Pasteur 10, 20014 Nerviano, MI, Italy. italo.beria@nervianoms.com
PMID: 21470862 DOI: 10.1016/j.bmcl.2011.03.054
Abstract

As part of our drug discovery effort, we identified and developed 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as PLK1 inhibitors. We now report the optimization of this class that led to the identification of NMS-P937, a potent, selective and orally available PLK1 Inhibitor. Also, in order to understand the source of PLK1 selectivity, we determined the crystal structure of PLK1 with NMS-P937. The compound was active in vivo in HCT116 xenograft model after oral administration and is presently in Phase I clinical trials evaluation.

Figures
Products